Mirvetuximab soravtansine

ELAHERE 5 mg/ml concentraat voor oplossing voor infusie

Concentraat voor oplossing voor infusieNetherlandsAuthorisedAuthorised 14 Nov 2024

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

ElahereEuropean UnionAuthorised

ElahereBrazil · Abbvie Farmacêutica Ltda.Same brand
ElahereCanada · 100 MG / 20 ML · Solution · Abbvie CorporationSame brand
Elahere 5 MG/ML Concentrado Para Solucion Para PerfusionSpain · 105,50 mg · concentrado para solución para perfusión · Abbvie Deutschland Gmbh & Co. KgSame brand
ElahereEuropean Union · AbbVie Deutschland GmbH & Co. KGSame brand
ElahereCroatiaSame brand
ElahereItaly · Concentrato per soluzione per infusione · Abbvie Deutschland GMBH & Co. KG

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Mirvetuximab soravtansine

ELAHERE 5 mg/ml concentraat voor oplossing voor infusie

Concentraat voor oplossing voor infusieNetherlandsAuthorisedAuthorised 14 Nov 2024

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

ElahereEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Elahere Concentrate for Solution for Infusion 100MG/20MLSingapore · 100mg/20mL · infusion, solution concentrate · Abbvie Pte. LTD.

ElahereUnited States · 100mg/20mL single-dose vial · injectable · Immunogen INC

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim · Added 8 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Mirvetuximab soravtansine
Dosage form: Concentraat voor oplossing voor infusie
Route: Intraveneus gebruik
Register: Netherlands (CBG-MEB)
Status: Authorised
Status in the register: Ingeschreven
Authorised: 14 Nov 2024
Registration: EU/1/24/1866
Marketing authorisation holder: AbbVie Deutschland GmbH & Co. KG
ATC code: L01FX26
Group: Antineoplastic and immunomodulating agents
Procedure: EU centralised
Supply: Uitsluitend recept
EMA product number: EMEA/H/C/005036
EU number: EU/1/24/1866